VIVS VIVOSIM LAB
-
VIVOSIM LAB Reported Earnings
Wednesday, August 12, 2026 · 12:00 AM ET
VIVOSIM LAB (VIVS) reported a loss of $0.25 per share on revenue of $0.02 million for the . . Revenue fell 51.35% compared to the same quarter a year ago.
VivoSim Labs Inc. is a clinical-stage biotechnology company. It involved in developing drugs which are demonstrated to be effective in three-dimensional human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease. VivoSim Labs Inc., formerly known as Organovo Holdings Inc., is based in SAN DIEGO, United States.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.25)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
$0.02M
Revenue Estimate
—
Revenue Surprise
Revenue Growth